BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Marceline Clementine Appointed Chief Financial Officer of Trophos


9/18/2012 9:31:24 AM

Marseille, France, September 18, 2012 - Trophos SA, a French pharmaceutical company developing innovative therapies in neurology and cardiology up to the clinical validation stage, announces today the appointment of Marceline Clementine as chief financial officer.

Marceline Clementine has more than 30 years experience in the world of finance. She joined Trophos in 2006 as administration and finance manager. Before that, she had worked as chief accountant or financial controller at various companies in the real estate and catering sectors, including Groupe FLO.

She is now responsible for all administrative and financial services at Trophos, as well as for human resources management. Marceline Clementine succeeds Christine Placet, the former chief financial officer, who has just been promoted to the post of chief executive officer of Trophos.

“We are delighted to welcome Marceline Clementine as chief financial officer,” said Christine Placet, the CEO of Trophos. “This appointment is a recognition of Ms. Clementine’s competence in financial matters and her strong commitment to Trophos over the past few years. Her financial management skills are a precious asset for the company. We are continuing our quest to find strategic partners for our current programs to guarantee the future of our company, which was founded 13 years ago now.”

Trophos has sufficient funding in hand to continue its research activities up to 2014. The company is currently undertaking several programs focused on the following drug candidates:

• Olesoxime in Spinal Muscular Atrophy (SMA): a pivotal study is underway and the results are expected in the second half of 2013.

• Olesoxime for multiple sclerosis (MS) disease progression: a phase II proof-of-concept study has been designed in conjunction with international MS specialists.

• TRO40303 cardiac protection compound: a phase IIa proof-of-concept study in cardiac ischemia-reperfusion injury (IRI) is underway and the results are expected in the first half of 2013.

About Trophos SA – http://www.trophos.com

Trophos is a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology. The company has a novel and proprietary cholesterol oxime based chemistry platform generating a pipeline of drug candidates. The lead product, olesoxime (TRO19622), is in a pivotal clinical study for Spinal Muscular Atrophy (substantially funded by the AFM patient association). Olesoxime is also ready for a phase II proof of concept study in Multiple Sclerosis (MS) disease progression. A second product, TRO40303, is in phase II clinical development to treat cardiac reperfusion injury (as part of an EU funded project, MitoCare). Trophos' mitochondrial pore modulator compounds enhance the function and survival of stressed cells via modulation of dysfunctional mitochondria through interactions at the permeability transition pore (mPTP). Recently published clinical studies support the therapeutic rationale for mitochondria targeted drugs, which Trophos is uniquely placed to exploit.

Trophos, founded in 1999, is based in Marseille, France and currently has 27 employees.

Mark Tidmarsh

ANDREW LLOYD & ASSOCIATES

http://www.ala.com

mark@ala.com

Follow us on Twitter: https://twitter.com/ALA_Group

Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND

Tel: +44 1273 675100 Fax: +44 1273 675400

55 rue Boissonade 75014 Paris FRANCE

Tel: +33 1 56 54 07 00 Fax: +33 1 56 54 07 01

INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION



Read at BioSpace.com

Trophos
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES